Abstract： Objective To observe the therapeutic effect of combined treatment with ezetimibe and evolocumab on patients with hypercholesterolemia and coronary heart disease (CHD), and the impact on blood lipid levels, cardiac function, and serum homocysteine (HCY), oxidized low-density lipoprotein (ox-LDL) and high-sensitivity C-reactive protein (hs-CRP) levels. Methods A total of 130 patients with hypercholesterolemia and CHD who were treated in the hospital from April 2023 to April 2024 were selected, and randomly assigned to the control group and the experimental group, with 65 cases in each group. Both groups received conventional treatment, with the control group receiving ezetimibe in addition to conventional treatment, and the experimental group receiving a combination of erlotinib and ezetimibe in addition to conventional treatment. Therapeutic effects, blood lipid levels, cardiac function, and serum HCY, ox-LDL and hs-CRP levels were observed, and evaluate its therapeutic safety. Results After treatment, therapeutic effect on CHD and lipid-lowering effect in the experimental group were significantly better compared to the control group. After treatment, the levels of total cholesterol (TC), triacylglycerol (TG) and low-density lipoprotein cholesterol (LDL-C) in the two groups decreased, and the levels of high-density lipoprotein cholesterol (HDL-C) increased. Meanwhile, the levels of TC, TG and LDL-C were lower, and the level of HDL-C was higher in the experimental group. Left ventricular ejection fraction (LVEF) in the two groups was significantly increased, and left ventricular end diastolic diameter (LVEDd) and left ventricular end systolic diameter (LVESd) were significantly reduced. LVEF in the experimental group was significantly higher. LVEDd and LVESd in the experimental group were significantly smaller. After treatment, the levels of HCY, ox-LDL and hs-CRP in the two groups were significantly reduced, and the levels were significantly lower in the experimental group. During the treatment period, no significant difference was found in the incidence of adverse reactions between the two groups. Conclusion The combined treatment with ezetimibe and evolocumab can achieve better therapeutic effects on patients with hypercholesterolemia and CHD. It can effectively improve patients’ blood lipid levels and cardiac function, and lower serum HCY, ox-LDL and hs-CRP levels, and the treatment has high safety.
2024, Vol. 21 
